Medical Device News Magazine

Varian Introduces Isolis Cryoprobe to Simplify Planning and Guidance During Cryoablation Procedures

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Varian, a Siemens Healthineers company, is introducing the Isolis™ cryoprobe, a single use, disposable device designed for use with CryoCare® systems* that seeks to improve procedural efficiency and precision for cryoablation. Cryoablation is a minimally invasive, image-guided procedure for treating disease and alleviating pain by very precisely freezing and destroying tissue targets such as tumors of the lung, liver, breast, kidney, prostate, and soft tissue.

The new Isolis cryoprobe offers the interventional radiologist greater operational control, with features designed to enhance predictability, precision, and efficiency.  It features a small 2.1mm/14-gauge shaft and a sharp probe tip to facilitate smooth and accurate placement.

Isolis is also the first cryoprobe to offer optional integration with the Siemens Healthineers myNeedle Laser** guidance system, which was developed for image-guided interventional procedures. The clinician can use myNeedle Laser to guide the insertion and trajectory of the cryoprobe while using imaging to monitor placement progress.

“The Isolis cryoprobe reflects the significant opportunity Varian has as a Siemens Healthineers company to seek to raise the standards of procedural efficiency and precision,” said Francis (Frank) Facchini, MD, President, Interventional Solutions at Varian.  “This exciting development represents the first new interventional radiology product since combining with Siemens Healthineers, and a first step towards our goal of making these impactful, minimally invasive treatment options easier to execute and more widely accessible to the patients who can benefit. We look forward to further collaboration and innovation on behalf of patients worldwide, as we continue to advance our mission to help create a world without fear of cancer.”

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

*CryoCare systems are intended for use in open, minimally invasive or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The systems are designed to freeze/ablate tissue by the application of extreme cold temperatures, including prostate and kidney tissue, liver metastases, tumors, skin lesions, and warts.

**myNeedle™ and myNeedle Laser are trademarks of Siemens Healthineers.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”